Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Obesity | Research article

COVID-19 and gastrointestinal symptoms in Mexico, a systematic review: does location matter?

Authors: Antonio Pizuorno, Nora A. Fierro, Edgar D. Copado-Villagrana, María E. Herrera-Solís, Gholamreza Oskrochi, Hassan Brim, Hassan Ashktorab

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

Covid-19 in Mexico is on the rise in different parts of the country. We aimed to study the symptoms and comorbidities that associate with this pandemic in 3 different regions of Mexico.

Methods

We analyzed data from SARS-CoV-2 positive patients evaluated at healthcare centers and hospitals of Mexico (n = 1607) including Northwest Mexico (Sinaloa state), Southeast Mexico (Veracruz state) and West Mexico (Jalisco state) between March 1 and July 30, 2020. Mexico consists of a total population that exceeds 128 million. Demographics, comorbidities and clinical symptoms were collected. Statistical descriptive analysis and correlation analyses of symptoms, comorbidities and mortality were performed.

Results

A total of 1607 hospitalized patients positive for COVID-19 across all 3 regions of Mexico were included. The average age was 54.6 years and 60.4% were male. A mortality rate of 33.1% was observed. The most common comorbidities were hypertension (43.2%), obesity (30.3%) and diabetes (31.4%). Hypertension was more frequent in West (45%), followed by Northwest (37%) and Southeast Mexico (29%). Obesity was around 30% in Northwest and West whereas an 18% was reported in Southeast. Diabetes was most common in West (34%) followed by Northwest (22%) and Southeast (13%). This might be related to the highest mortality rate in Northwest (31%) and West (37%) when compared to Southeast. Most common symptoms in our overall cohort were fever (80.8%), cough (79.8%), headache (66%), dyspnea (71.1%), myalgia (53.8%), joints pain (50.8%) and odynophagia (34.8%). Diarrhea was the main gastrointestinal (GI) symptom (21.3%), followed by abdominal pain (18%), and nausea/ vomiting (4.5%). Diarrhea and abdominal pain were more common in West (23.1 and 21%), followed by Southeast (17.8, and 9.8%) and Northwest (11.4 and 3.1%).

Conclusion

Our study showed a high mortality rate likely related to high frequencies of comorbidities (hypertension, obesity and diabetes). Mortality was different across regions. These discrepancies might be related to the differences in the frequencies of comorbidities, and partially attributed to differences in socio-economic conditions and quality of care. Thus, our findings stress the need for improved strategies to get better outcomes in our population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Odometer W. The cases/deaths of Covid-19 for South America plus North America; 2020. Odometer W. The cases/deaths of Covid-19 for South America plus North America; 2020.
2.
go back to reference Secretary of Health of Mexico, National Institute of Statistics and Geography, National Institute of Public Health. National Health and Nutrition Survey 2018. 2019. Secretary of Health of Mexico, National Institute of Statistics and Geography, National Institute of Public Health. National Health and Nutrition Survey 2018. 2019.
9.
go back to reference Ministry of Health Mexico, General Directorate of Health Information. 2020. Ministry of Health Mexico, General Directorate of Health Information. 2020.
10.
go back to reference Villagrán-Olivas KA, Alejandro T-ZL, Adolfo E-G. Clinical-epidemiological characteristics of COVID-19 patients in a Hospital of Sinaloa, México. REVMEDUAS. 2020;10:65–79. Villagrán-Olivas KA, Alejandro T-ZL, Adolfo E-G. Clinical-epidemiological characteristics of COVID-19 patients in a Hospital of Sinaloa, México. REVMEDUAS. 2020;10:65–79.
12.
go back to reference Giannouchos TV, et al. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. Eur Respir J. 2020. Giannouchos TV, et al. Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases. Eur Respir J. 2020.
13.
go back to reference Garibaldi BT, et al. Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. Ann Intern Med. 2020. Garibaldi BT, et al. Patient Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. Ann Intern Med. 2020.
15.
go back to reference Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation BMJ. 2015;350:1-25. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation BMJ. 2015;350:1-25.
17.
go back to reference Report, N.H.a.N.S.R., Presentation of results National Health and Nutrition Survey Results Report - 2020. Report, N.H.a.N.S.R., Presentation of results National Health and Nutrition Survey Results Report - 2020.
18.
go back to reference Policy, N.E.C.o.t.S.D., Vulnerable and historically discriminatory groups in the context of the sanitary emergency caused by the SARS-CoV-2 virus (COVID-2019). 2020. Policy, N.E.C.o.t.S.D., Vulnerable and historically discriminatory groups in the context of the sanitary emergency caused by the SARS-CoV-2 virus (COVID-2019). 2020.
19.
go back to reference Security. MIoS: Interim algorithms for the care of COVID-19. 2020. Security. MIoS: Interim algorithms for the care of COVID-19. 2020.
Metadata
Title
COVID-19 and gastrointestinal symptoms in Mexico, a systematic review: does location matter?
Authors
Antonio Pizuorno
Nora A. Fierro
Edgar D. Copado-Villagrana
María E. Herrera-Solís
Gholamreza Oskrochi
Hassan Brim
Hassan Ashktorab
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06252-y

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.